3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Gastrointestinal
1
CNS
1
Conditions
Neoplasms
2
Colorectal Neoplasms
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Rectal Neoplasms
1
Neuroblastoma
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Liver Neoplasms
1
Laryngeal Diseases
1
Hematologic Neoplasms
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Interventions
Magnetic Resonance Spectroscopy
11
Specimen Handling
8
X-Rays
7
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
6
Biopsy
6
olaparib
4
ulixertinib
3
trametinib
3
palbociclib
3
larotrectinib
3
ivosidenib
3
erdafitinib
3
dabrafenib
3
Vemurafenib
3
tipifarnib
2
tazemetostat
2
selpercatinib
2
ensartinib
2
durvalumab
2
Nivolumab
2
LY3023414
2
Gemcitabine
2
Doxorubicin
2
Docetaxel
2
Cisplatin
2
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
sonidegib
1
sargramostim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioma
×
capmatinib
×
Gastrointestinal
×
Clear all
NCT06988475
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled